Copyright © 2021. Inderes Oyj. All rights reserved.

Nexstim

Viimeisimmät raportit

Laaja raportti

Analyst

Antti Siltanen

Antti Siltanen

Analyytikko

Read more

Viimeisin video

Latest insider trading

Net impact profile

Third party research
9.9.
2022

We give a short comment on the recent FDA clearance for Nexstim’s partner Magnus Medical.

Tiedotteet
25.8.
2022

Nexstim Receives an NBS System Order from a Customer in Europe

Press release, Helsinki, 25 August 2022 at 10 AM (EET)

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an NBS 5 System order from a customer in Europe. The customer is a new user of the Nexstim NBS system, acquiring the system to enable future neuroscience projects.

Tiedotteet
19.8.
2022

Redeye raises its full-year sales estimates for 2022E from EUR 7.6m to EUR 10.2m but lower our 2023-2024 estimates by 7-20% following the report and licensing agreement with Magnus Medical. We continue to see good prospects in Nexstim but argue that the slowing growth in the NBT segment and upcoming licensing period add some uncertainty to the case for growth in the upcoming years. We slightly lower our base case to SEK 62.5 per share.

Third party research
19.8.
2022

Redeye raises its full-year sales estimates for 2022E from EUR 7.6m to EUR 10.2m but lower our 2023-2024 estimates by 7-20% following the report and licensing agreement with Magnus Medical.

Tiedotteet
17.8.
2022

Nexstim Plc: Managers’ Transactions, Weckroth

Company Announcement, Helsinki, 17 August 2022 at 9 AM (EET)

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces managers’ transactions as follows:

Person subject to the notification requirement
Name: Tero Weckroth
Position: Member of the Board/Deputy member

inderesTV
Nexstim, analyst Antti Siltanen
16.8.
2022

Nexstim is a medical technology company, whose transcranial magnetic stimulation technology is used in pre-operative brain mapping and to treat neurological diseases and disorders. This technologically advanced niche player has a commercialization in relatively early stages and has been loss-making throughout its history. This year we expect a profitable result, supported by a non-recurring license fee. Analyst Antti Siltanen guides through technology, income streams, business model, future outlook and valuation.

Content:
00:00 Introduction

Analyysi
16.8.
2022

Nexstim is a medical technology company whose magnetic stimulation technology is used in pre-operative brain mapping and to treat neurological diseases and disorders. The company is a technologically advanced niche player in large markets supported by megatrends. Nexstim’s commercialization is still in relatively early stages, but major losses are becoming a thing of the past. Share valuation relies strongly on future expectations, especially on growth in recurring net sales. Thus, the investor has to bear the risk of expectations materializing.

Tiedotteet
12.8.
2022

Company announcement, Helsinki, August 12, 2022 at 9 am (EEST)

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2022 (UNAUDITED)

THE BEST HALF-YEAR IN NEXSTIM’S HISTORY IN TERMS OF NET SALES AND OPERATING RESULT

Tiedotteet
8.8.
2022

Company announcement, Helsinki, 8 August 2022 at 10 AM (EEST)

Notice of Nexstim Plc’s Half-Yearly Report H1 2022

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") will publish its half-yearly report for the six months ended 30 June 2022 on Friday 12 August 2022 at approximately 9:00 am Finnish time.

Tiedotteet
19.7.
2022

Press release, Helsinki, 19 July 2022 at 10 AM (EET)

Nexstim Receives an NBS System Order from a Finnish Customer

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an order for NBS 5 system from a hospital in Finland.

Nexstim

English translation unavailable for Nexstim.